drugset
drugset / Trial / NCT04991935

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

NCT04991935 ↗

Phase 3 Completed 367 enrolled Celgene Corporation
NaSingle-groupOpen-labelTreatment

Summary

This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will enroll participants who participated in the CC-93538-EE-001 or CC-93538-DDI-001 studies.

Timeline

Start
2022-08-09
Primary completion
2025-08-14
Completion
2025-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Cendakimab Monoclonal antibody — Subcutaneous

Indications

eosinophilic esophagitis